Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endp

[News]

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

More... (http://www.news-medical.net/news/20100224/Novelos-Therapeutics-NOV-002-Phase-3-NSCLC-trial-fails-to-meet-primary-survival-endpoint.aspx)